icon-folder.gif   Conference Reports for NATAP  
  66th Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 13-17 2015
Back grey_arrow_rt.gif
Improvement in Liver Disease Parameters Following Treatment with Daclatasvir + Sofosbuvir and Ribavirin in Patients With Chronic HCV Infection and Advanced Cirrhosis
  "ALT, direct bilirubin, albumin, APRI, and FibroTest scores showed similar degrees of improvement across all Child-Pugh classes......Improvements in INR and MELD scores were most evident in patients with class C disease, and improvements in MELD score were more frequent in patients who achieved SVR12."
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
RJ Fontana,1 F Poordad,2 ER Schiff,3 JM Vierling,4 C Landis,5 R Bhore,6 PD Yin,7 S Noviello,6 ES Swenson7
1University of Michigan Medical Center, Ann Arbor, MI; 2Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX; 3Schiff Center for Liver Diseases, University of Miami Miller School of Medicine, Miami, FL; 4Baylor College of Medicine, Houston, TX; 5University of Washington School of Medicine, Seattle, WA; 6Bristol-Myers Squibb, Princeton, NJ; 7Bristol-Myers Squibb, Wallingford, CT.